Alessia Bellotti

Alessia Bellotti

Auto-generated profile, based on publicly available information

Alessia Bellotti

University of Perugia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2025 in Cephalalgia
Verified
Journal Article
Open access
RORaffaele Ornello
Raffaele Ornello
VCValeria Caponnetto
Valeria Caponnetto
FAFayyaz Ahmed
Fayyaz Ahmed
HAHaidar M. Al-Khazali
Haidar M. Al-Khazali
AAAnna Ambrosini
Anna Ambrosini
SSSimona Sacco
Simona Sacco
We here present evidence-based guidelines for the pharmacological treatment of migraine. These guidelines, created by the Italian Society for the Study of Headache and the International Headache Society, aim to offer clear, actionable recommendations to healthcare professionals. They incorporate evidence-based recommendations from randomized controlled trials and expert-based opinions. The guidelines follow the Grading of Recommendations, Assessment, Development and Evaluation approach for assessing the quality of evidence. The guideline development involved a systematic review of literature across multiple databases, adherence to Cochrane review methods, and a structured framework for data extraction and interpretation. Although the guidelines provide a robust foundation for migraine treatment, they also highlight gaps in current research, such as the paucity of head-to-head drug comparisons and the need for long-term outcome studies. These guidelines serve as a resource to standardize migraine treatment and promote high-quality care across different healthcare settings.

25 April 2025 in Cephalalgia
Verified
Journal Article
Open access
RORaffaele Ornello
Raffaele Ornello
VCValeria Caponnetto
Valeria Caponnetto
FAFayyaz Ahmed
Fayyaz Ahmed
HAHaidar M Al-Khazali
Haidar M Al-Khazali
AAAnna Ambrosini
Anna Ambrosini
SSSimona Sacco
Simona Sacco
We here present evidence-based guidelines for the pharmacological treatment of migraine. These guidelines, created by the Italian Society for the Study of Headache and the International Headache Society, aim to offer clear, actionable recommendations to healthcare professionals. They incorporate evidence-based recommendations from randomized controlled trials and expert-based opinions. The guidelines follow the GRADE approach for assessing the quality of evidence. The guideline development involved a systematic review of literature across multiple databases, adherence to Cochrane review methods, and a structured framework for data extraction and interpretation. Although the guidelines provide a robust foundation for migraine treatment, they also highlight gaps in current research, such as the paucity of head-to-head drug comparisons and the need for long-term outcome studies. These guidelines serve as a resource to standardize migraine treatment and promote high-quality care across different healthcare settings.

29 January 2025 in Cephalalgia Reports
Verified
Journal Article
Open access
ABAlessia Bellotti
Alessia Bellotti
CPCaterina Podella
Caterina Podella
PSPaola Sarchielli
Paola Sarchielli
Background and Aim: Eptinezumab is a quarterly intravenous infusion monoclonal antibody (mAb) with high affinity for calcitonin gene related peptide (CGRP) and a long-lasting mechanism of action. In our retrospective observational study, we sought to investigate the effectiveness and safety of eptinezumab both in mAbs-naïve and mAbs-non responders’ patients. Methods: We collected clinical data from electronic charts of 30 migraineurs who underwent six months of eptinezumab treatment; 18 patients had never undergone mAbs-prophylaxis (G1) while 12 had been non-responders to erenumab/galcanezumab (G2). Monthly Headache Days (MHDs), MIDAS, HIT6 and ASC scores were recorded before eptinezumab (T0) and thereafter every three months. Patients were considered responders whenever MHDs reduction was >50% at six months (T2). Results: Overall, 25 out of 30 patients (15 in G1 and 10 in G2) were eptinezumab responders (83.3%). Headache frequency (MHDs) at T0 was 12.4 in G1 and 17.0 in G2, while at T2 it was 7.1 in G1 and 8.0 in G2 (p-value < 0.0001). Significant reductions in MIDAS, HIT6 and ASC scores were also observed. No safety concerns were registered. Conclusions: Based upon our retrospective observational study, eptinezumab might be effective and safe also for those migraineurs who resulted being non-responders to other anti-CGRP(R) mAbs.

17 June 2026 in Cephalalgia
Verified
Journal Article
Open access
DCDavide Chiasserini
Davide Chiasserini
ABAlessia Bellotti
Alessia Bellotti
AMAlfredo Megaro
Alfredo Megaro
Giuseppe TringaliGiuseppe Tringali
Giuseppe Tringali
ICIlenia Corbelli
Ilenia Corbelli
PSPaola Sarchielli
Paola Sarchielli
Aim: Calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) play a crucial role in migraine pathophysiology. In recent years, anti-CGRP(R) monoclonal antibodies (mAbs) have emerged as the first targeted and highly effective therapy for migraine. This study aimed to assess any changes in plasma CGRP levels following prophylactic treatment with anti-CGRP(R) mAbs and to compare CGRP dynamics between anti-receptor (erenumab) and anti-ligand (galcanezumab, fremanezumab) therapies. Secondary objectives were: (i) to evaluate changes in VIP and PACAP plasma levels following treatment with anti-CGRP(R) mAbs and (ii) to investigate whether baseline or post-treatment plasma levels of CGRP, VIP and PACAP were associated with clinical response to anti-CGRP(R) monoclonal antibody therapy. Methods: Between February 2022 and February 2023, we enrolled 56 migraine patients who initiated prophylaxis with either erenumab (26 patients), galcanezumab (16 patients) or fremanezumab (14 patients). Responders were defined as those achieving a ≥50% reduction in monthly migraine days after six months. Blood samples were collected at baseline and at each follow-up visit (baseline, T0; three months, T1; six months, T2; 12 months, T3). Plasma levels of CGRP, VIP and PACAP were measured using a validated radioimmunoassay and commercially available enzyme-linked immunosorbent assay kits. Results: Overall, 80.3% (45 out of 56) of patients responded to anti-CGRP(R) mAbs. No correlation was found between baseline CGRP, VIP and PACAP plasma levels and clinical response to anti-CGRP(R) mAbs therapy. Regarding CGRP trend, significant differences were found between patients treated with the anti-receptor monoclonal antibody (erenumab) and those receiving anti-ligand therapies. In patients treated with erenumab, CGRP levels did not show a significant change over the treatment period (T1–T3), whereas, in the galcanezumab group, CGRP levels significantly decreased as early as T1 ( p < 0.01). CGRP longitudinal assessment of the fremanezumab group were excluded due to assay interference with the drug. VIP and PACAP plasma levels remained stable over time for all treatments, with no significant differences between responders and non-responders. Conclusions: Galcanezumab reduced CGRP plasmatic levels already after three months, whereas erenumab did not affect significantly CGRP plasmatic levels. VIP and PACAP levels were not influenced by the therapy.

15 September 2026 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
ABAlessia Bellotti
Alessia Bellotti
RNRoberta Noseda
Roberta Noseda
RMRoberto Masciullo
Roberto Masciullo
CSClaudio Staedler
Claudio Staedler
CGClaudio Gobbi
Claudio Gobbi
CZChiara Zecca
Chiara Zecca